IL160139A0 - Spiro compounds - Google Patents

Spiro compounds

Info

Publication number: IL160139A0
Authority: IL; Israel
Prior art keywords: alk; optionally substituted; aryl; nhalk; oalk
Prior art date: 2001-08-07

Application number

IL16013902A

Other languages

English (en)

Original Assignee

Banyu Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-07

Filing date

2002-08-02

Publication date

2004-06-20

2002-08-02 Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd

2004-06-20 Publication of IL160139A0 publication Critical patent/IL160139A0/xx

Links

150000003413 spiro compounds Chemical class 0.000 title abstract 3
125000003118 aryl group Chemical group 0.000 abstract 5
125000001475 halogen functional group Chemical group 0.000 abstract 3
125000002947 alkylene group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000004438 haloalkoxy group Chemical group 0.000 abstract 2
125000001188 haloalkyl group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
101500025005 Homo sapiens Neuropeptide Y Proteins 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
230000001195 anabolic effect Effects 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000001539 anorectic effect Effects 0.000 abstract 1
230000002075 anti-alcohol Effects 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002402 anti-lipaemic effect Effects 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
125000000732 arylene group Chemical group 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
XKWCTHKJQNUFOQ-HRPSIEBRSA-N gtpl1504 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 XKWCTHKJQNUFOQ-HRPSIEBRSA-N 0.000 abstract 1
125000005549 heteroarylene group Chemical group 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940125725 tranquilizer Drugs 0.000 abstract 1
239000003204 tranquilizing agent Substances 0.000 abstract 1
230000002936 tranquilizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL16013902A 2001-08-07 2002-08-02 Spiro compounds IL160139A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001239567		2001-08-07
PCT/JP2002/007922 WO2003014083A1 (fr)	2001-08-07	2002-08-02	Composes spiro

Publications (1)

Publication Number	Publication Date
IL160139A0 true IL160139A0 (en)	2004-06-20

Family

ID=19070298

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16013902A IL160139A0 (en)	2001-08-07	2002-08-02	Spiro compounds

Country Status (18)

Country	Link
US (1)	US7205417B2 (fr)
EP (1)	EP1415986B1 (fr)
JP (1)	JP4341404B2 (fr)
KR (1)	KR20040023731A (fr)
CN (1)	CN1538956A (fr)
AT (1)	ATE427935T1 (fr)
AU (1)	AU2002323787B2 (fr)
BR (1)	BR0211740A (fr)
CA (1)	CA2456599A1 (fr)
DE (1)	DE60231880D1 (fr)
EA (1)	EA006964B1 (fr)
HU (1)	HUP0401108A2 (fr)
IL (1)	IL160139A0 (fr)
MX (1)	MXPA04001144A (fr)
NO (1)	NO20040534L (fr)
PL (1)	PL367983A1 (fr)
WO (1)	WO2003014083A1 (fr)
ZA (1)	ZA200400091B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6374762B1 (en) *	1997-10-27	2002-04-23	Correct Craft, Inc.	Water sport towing apparatus
ES2193875B2 (es) *	2002-04-09	2005-03-01	Laboratorios Del Dr. Esteve, S.A.	Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
US20040242572A1 (en) *	2002-08-24	2004-12-02	Boehringer Ingelheim International Gmbh	New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
NZ543102A (en)	2003-04-24	2008-12-24	Incyte Corp	Aza spiro alkane derivatives as inhibitors of metalloproteases
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
US20060122197A1 (en) *	2004-08-10	2006-06-08	Wenqing Yao	Amido compounds and their use as pharmaceuticals
US7786141B2 (en)	2004-08-19	2010-08-31	Vertex Pharmaceuticals Incorporated	Dihydrospiroindene modulators of muscarinic receptors
TW200621244A (en)	2004-08-19	2006-07-01	Vertex Pharma	Modulators of muscarinic receptors
EP1795527B1 (fr) *	2004-09-07	2009-04-22	Banyu Pharmaceutical Co., Ltd.	Composé spiro substitué par un groupement carbamoyle
JP2008521825A (ja) *	2004-11-29	2008-06-26	バーテックスファーマシューティカルズインコーポレイテッド	ムスカリン受容体のモジュレーター
BRPI0616463A2 (pt)	2005-09-29	2011-06-21	Merck & Co Inc	composto, composição farmacêutica, e, uso de um composto
US8158791B2 (en) *	2005-11-10	2012-04-17	Msd K.K.	Aza-substituted spiro derivatives
UA94433C2 (en) *	2005-11-10	2011-05-10	Баниу Фармасьютикал Ко., Лтд.	Aza-substituted spiro derivative
US7858635B2 (en)	2005-12-22	2010-12-28	Vertex Pharmaceuticals Incorporated	Spiro compounds as modulators of muscarinic receptors
CN101426499A (zh)	2006-02-22	2009-05-06	弗特克斯药品有限公司	毒蕈碱受体调节剂
NZ570497A (en)	2006-02-22	2011-09-30	Vertex Pharma	Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
US7910108B2 (en)	2006-06-05	2011-03-22	Incyte Corporation	Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
CN101500565A (zh)	2006-06-29	2009-08-05	弗特克斯药品有限公司	毒蕈碱性受体的调节剂
EP2051712A2 (fr) *	2006-08-15	2009-04-29	Vertex Pharmceuticals Incorporated	Modulateurs de récepteurs muscariniques
WO2008021545A2 (fr) *	2006-08-18	2008-02-21	Vertex Pharmaceuticals Incorporated	Modulateurs des récepteurs muscariniques
JP5489333B2 (ja)	2006-09-22	2014-05-14	メルク・シャープ・アンド・ドーム・コーポレーション	脂肪酸合成阻害剤を用いた治療の方法
CA2682727C (fr)	2007-04-02	2016-03-22	Banyu Pharmaceutical Co., Ltd.	Derive d'indoledione
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (fr)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
MX2010003373A (es) *	2007-10-03	2010-04-30	Vertex Pharma	Moduladores de receptores muscarinicos.
JP5451646B2 (ja) *	2008-02-27	2014-03-26	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
EP2810951B1 (fr)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010047982A1 (fr)	2008-10-22	2010-04-29	Merck Sharp & Dohme Corp.	Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
JP5635991B2 (ja)	2008-10-30	2014-12-03	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	イソニコチンアミドオレキシン受容体アンタゴニスト
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
CN102656147A (zh) *	2009-12-11	2012-09-05	霍夫曼-拉罗奇有限公司	可用作ampk调节剂的螺吲哚-环丙烷二氢吲哚酮
WO2011069298A1 (fr)	2009-12-11	2011-06-16	F. Hoffmann-La Roche Ag	Nouveaux dérivés de cyclopropane indolinone
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
BR112013021236B1 (pt)	2011-02-25	2021-05-25	Merck Sharp & Dohme Corp	composto derivado de benzimidazol, e, composição
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US8975398B2 (en)	2012-05-11	2015-03-10	Abbvie Inc.	NAMPT inhibitors
ES2704744T3 (es)	2012-06-13	2019-03-19	Incyte Holdings Corp	Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9527875B2 (en)	2012-08-02	2016-12-27	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
RU2015140066A (ru)	2013-02-22	2017-03-30	Мерк Шарп И Доум Корп.	Противодиабетические бициклические соединения
WO2014139388A1 (fr)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
CA2905435A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions utiles pour le traitement de troubles gastro-intestinaux
CA2905438A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase et leurs utilisations
EA035095B1 (ru)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
SI3004138T1 (sl)	2013-06-05	2024-07-31	Bausch Health Ireland Limited	Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (fr)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Composés tricycliques antidiabétiques
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr)	2015-02-20	2016-08-25	Incyte Corporation	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es)	2015-02-20	2020-04-24	Incyte Holdings Corp	Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
US11072602B2 (en)	2016-12-06	2021-07-27	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (fr)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Composés de spirochromane antidiabétiques
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es)	2018-05-04	2021-04-26	Incyte Corp	Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
WO2020167701A1 (fr)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Agonistes du récepteur de l'orexine de type pyrrolidine
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
WO2020185532A1 (fr)	2019-03-08	2020-09-17	Incyte Corporation	Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr)	2019-07-09	2021-01-14	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US12312332B2 (en)	2019-08-08	2025-05-27	Merck Sharp & Dohme Llc	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2021067374A1 (fr)	2019-10-01	2021-04-08	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (fr)	2019-10-16	2021-04-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP4069696A1 (fr)	2019-12-04	2022-10-12	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
BR112022010664A2 (pt)	2019-12-04	2022-08-16	Incyte Corp	Derivados de um inibidor de fgfr
WO2021146424A1 (fr)	2020-01-15	2021-07-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
BR112023002957A2 (pt)	2020-08-18	2023-04-04	Merck Sharp & Dohme Llc	Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
CN112939864B (zh) *	2021-01-29	2022-05-06	中国医科大学	螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
WO2022261159A1 (fr)	2021-06-09	2022-12-15	Incyte Corporation	Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
EP4352059A1 (fr)	2021-06-09	2024-04-17	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5869489A (en) *	1996-03-25	1999-02-09	Merck & Co., Inc.	Trypthophan ureas as neurokinnin antagonists
GB2311523A (en) *	1996-03-25	1997-10-01	Merck & Co Inc	Tryptophan urea tachykinin receptor antagonists
AU1285499A (en)	1997-10-30	1999-05-24	Merck & Co., Inc.	Somatostatin agonists
ATE314371T1 (de)	1998-11-10	2006-01-15	Merck & Co Inc	Spiro-indole als y5-rezeptor antagonisten
WO2001014328A2 (fr) *	1999-08-20	2001-03-01	Merck & Co., Inc.	Urees substituees inhibiteurs d'adhesion cellulaire
US6803372B2 (en) *	1999-08-20	2004-10-12	Banyu Pharmaceutical Co., Ltd.	Spiro compounds
TWI279402B (en) *	1999-08-20	2007-04-21	Banyu Pharma Co Ltd	Spiro compounds having NPY antagonistic activities and agents containing the same
AU2001286242A1 (en) *	2000-09-14	2002-03-26	Toray Industries, Inc	Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
BR0116113A (pt) *	2000-12-12	2004-08-03	Neurogen Corp	Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas
JP4554202B2 (ja) *	2001-07-24	2010-09-29	メルク・シャープ・エンド・ドーム・コーポレイション	放射性標識神経ペプチドｙｙ５受容体拮抗薬

2002
- 2002-08-02 AT AT02755790T patent/ATE427935T1/de not_active IP Right Cessation
- 2002-08-02 CA CA002456599A patent/CA2456599A1/fr not_active Abandoned
- 2002-08-02 PL PL02367983A patent/PL367983A1/xx not_active Application Discontinuation
- 2002-08-02 JP JP2003519033A patent/JP4341404B2/ja not_active Expired - Fee Related
- 2002-08-02 IL IL16013902A patent/IL160139A0/xx unknown
- 2002-08-02 DE DE60231880T patent/DE60231880D1/de not_active Expired - Lifetime
- 2002-08-02 EP EP02755790A patent/EP1415986B1/fr not_active Expired - Lifetime
- 2002-08-02 US US10/485,955 patent/US7205417B2/en not_active Expired - Fee Related
- 2002-08-02 MX MXPA04001144A patent/MXPA04001144A/es unknown
- 2002-08-02 HU HU0401108A patent/HUP0401108A2/hu unknown
- 2002-08-02 EA EA200400288A patent/EA006964B1/ru not_active IP Right Cessation
- 2002-08-02 AU AU2002323787A patent/AU2002323787B2/en not_active Ceased
- 2002-08-02 WO PCT/JP2002/007922 patent/WO2003014083A1/fr not_active Ceased
- 2002-08-02 KR KR10-2004-7001947A patent/KR20040023731A/ko not_active Withdrawn
- 2002-08-02 CN CNA028153073A patent/CN1538956A/zh active Pending
- 2002-08-02 BR BR0211740-1A patent/BR0211740A/pt not_active IP Right Cessation
2004
- 2004-01-07 ZA ZA200400091A patent/ZA200400091B/en unknown
- 2004-02-05 NO NO20040534A patent/NO20040534L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20040023731A (ko)	2004-03-18
WO2003014083A1 (fr)	2003-02-20
CN1538956A (zh)	2004-10-20
EP1415986B1 (fr)	2009-04-08
NO20040534L (no)	2004-03-23
CA2456599A1 (fr)	2003-02-20
ZA200400091B (en)	2005-06-07
EA006964B1 (ru)	2006-06-30
PL367983A1 (en)	2005-03-21
DE60231880D1 (de)	2009-05-20
ATE427935T1 (de)	2009-04-15
US20040259890A1 (en)	2004-12-23
EA200400288A1 (ru)	2004-12-30
MXPA04001144A (es)	2004-07-08
BR0211740A (pt)	2004-09-28
AU2002323787B2 (en)	2008-04-24
EP1415986A1 (fr)	2004-05-06
EP1415986A4 (fr)	2005-11-02
JP4341404B2 (ja)	2009-10-07
US7205417B2 (en)	2007-04-17
JPWO2003014083A1 (ja)	2004-11-25
HUP0401108A2 (hu)	2004-09-28

Publication	Publication Date	Title
IL160139A0 (en)	2004-06-20	Spiro compounds
DE60330407D1 (de)	2010-01-14	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
DE602004005886D1 (de)	2007-05-24	Derivate von n-äphenyl(alkylpiperidin-2-yl)methylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
IL145830A0 (en)	2002-07-25	Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1
TW345575B (en)	1998-11-21	Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound
PT1349843E (pt)	2005-09-30	Derivados de tiazolo e de oxazolo como activadores dos receptores activados por proliferadores de peroxissomas humanos
RU2004134564A (ru)	2005-08-10	Химические соединения
ATE496622T1 (de)	2011-02-15	Verwendung von thienopyridonderivaten als ampk- aktivatoren und pharmazeutische zusammensetzungen,die diese enthalten
DE69300261D1 (de)	1995-08-24	Cyano-2-Hydroxy-3-Enamid-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, diese enthaltende pharmazeutische Zusammensetzungen und erhaltene Zwischenprodukte.
ATE206122T1 (de)	2001-10-15	Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
RU2009147775A (ru)	2011-08-27	Замещенные производные гетероарилпиперидина в качестве модуляторов рецептора меланокортина-4
DE60206111D1 (de)	2005-10-20	Selbstbräunendes Mittel enthaltend einen Ester von einer N-Acyl Aminosäure
JP2004523557A5 (fr)	2005-12-22
BR9707566A (pt)	1999-07-27	Derivados feniletanolamino tetralincarboxamida 3,4-dissubstituidos
ATE444965T1 (de)	2009-10-15	Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
DE69210647D1 (de)	1996-06-20	1,2,4-Triazolo[1,5-a]pyrimidinderivate, Verfahren zu ihrer Herstellung, diese enthaltende Arzneimittel und ihre Verwendung
ATE303991T1 (de)	2005-09-15	Aralkyltetrahydropyridine, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
ATE250586T1 (de)	2003-10-15	Imidazoline derivate,ihre herstellung und pharmazeutische zusammensetzungen die sie enthalten
DE69812010D1 (de)	2003-04-17	4-Aminopyrrole (3,2-d) Pyrimidinen als Antagonisten des Neuropeptide Y Receptors
ATE124685T1 (de)	1995-07-15	4-phenylmethyl-1h-indol-derivate, verfahren und zwischenverbindungen zu deren herstellung, anwendung als arzneimittel und diese enthaltende zusammensetzungen.
PL1968957T3 (pl)	2010-06-30	Podstawione tiazole i ich zastosowanie do wytwarzania środków leczniczych
DE502006007450D1 (de)	2010-08-26	Neue, zyklisch substituierte furopyrimidin-derivate und ihre verwendung zur behandlung von kardiovaskulären erkrankungen
ES2189355T3 (es)	2003-07-01	Compuestos de benzotiofeno como agentes antitromboticos e intermedios.